Figure 1 A hierarchy of steps need to be

Slides:



Advertisements
Similar presentations
$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.
Advertisements

Policy and Ethics – Donors Cadaveric versus Living Donors Amy Lu, MD Georgetown University David Cronin, MD, PhD University of Chicago.
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 2 Recruitment of experts to the Delphi study
Nat. Rev. Urol. doi: /nrurol
Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology
Nat. Rev. Urol. doi: /nrurol
Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Urol. doi: /nrurol
Volume 199, Issue 5, Pages (May 2018)
Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2
Figure 5 Two approaches to therapeutic genome editing
Figure 2 Peptide vaccination using TAA-derived long peptides
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Optimizing Management of Advanced Bladder Cancer
Figure 1 Key elements of the proposed modified Delphi study
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 6 Common signalling mechanisms, pathways,
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Immunotherapy for cSCC
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 The development process of the Asian
Figure 1 Differences in bladder cancer between genders
Nat. Rev. Urol. doi: /nrurol
Figure 3 Treatment algorithm for adult infertile men with varicoceles
Figure 3 Algorithm for the determination of the clinical
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Urol. doi: /nrurol
Figure 3 Multi-hit model for autoimmune diseases
Figure 6 Image sequence demonstrating coronal cuts on MRI
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 3 Differences in renal cell carcinoma (RCC) between genders
Figure 3 Template for standard pelvic lymphadenectomy
Nat. Rev. Urol. doi: /nrurol
Figure 2 Site of action of checkpoint inhibitors and agonists being
the SNP profile using 26 prostate cancer GWAS risk SNPs
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 1 Mechanisms of oncolytic-virus-based cancer therapy
Nat. Rev. Urol. doi: /nrurol
Figure 5 Design of mushroom flap for glansplasty
Nat. Rev. Urol. doi: /nrurol
Figure 4 The grey zone between active
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
The Nurse View.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Presentation transcript:

Figure 1 A hierarchy of steps need to be accomplished for success of a penile transplantation programme Figure 1 | A hierarchy of steps need to be accomplished for success of a penile transplantation programme. First, surgical ethics must be taken into consideration and social acceptance is required to ensure that potential donors and their families are willing to take part in the programme. Potential candidates for transplantation need to be recruited and then once all these features are in place the transplant procedure itself can be optimized. Both short-term and long-term adverse effects of a penile transplant for the patient must be considered and minimized before the programme can be considered a success. Siefker-Radtke, A. & Curti, B. (2017) Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition Nat. Rev. Urol. doi:10.1038/nrurol.2017.190